Source: International Congress 2015 – Immune mechanisms in the human lung
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Roland Buhl (Mainz, Germany), Roland Buhl, Kai-Michael Beeh, Wolfgang Timmer, Piet Cornelissen, Ralf Sigmund, Ashish Sharma, Michael Engel, Petra Moroni-Zentgraf, Ronald Dahl. 24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma. Eur Respir J 2015; 46: Suppl. 59, 4042

Member's Comments

No comment yet.

Related content which might interest you: 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014 Comparison of the pharmacokinetics and pharmacodynamics of once daily tiotropium Respimat® and tiotropium HandiHaler® in COPD patients Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 LATE-BREAKING ABSTRACT: Safety and tolerability of once-daily tiotropium Respimat® add-on therapy in children with moderate symptomatic asthma Source: International Congress 2016 – Living with asthma around the globe Year: 2016 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 The add-on effect of tiotropium bromide to ICS/LABA combination inhaler for the patients with severe uncontrolled asthma Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Assessment of the bioequivalence of two DPIs containing fluticasone and salmeterol, in patients with controlled or partly controlled asthma Source: International Congress 2016 – Clinical characteristics of asthma Year: 2016 Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Mixed treatment analysis comparing tiotropium HandiHaler® and Respimat® Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Add-on effects of long-acting beta2-agonists salmeterol inhaler vs tulobuterol patch in adult patients with mild-to-moderate asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Efficacy and safety of extrafine glycopyrronium bromide pMDI (CHF 5259) in COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Pharmacokinetics (PK), safety and tolerability of abediterol and mometasone furoate fixed- and free-dose combinations in healthy subjects Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS) Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015 Pharmacokinetics, safety and tolerability of CHF5993 a triple pMDI in renal impaired patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016